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The recent successes of genome-wide association studies and
the promises of whole genome sequencing fuel interest in the
translation of this new wave of basic genetic knowledge to
healthcare practice. Knowledge about genetic risk factors may
be used to target diagnostic, preventive, and therapeutic
interventionsforcomplexdisordersbasedonaperson’sgenetic
risk or to complement existing risk models based on classic
non-genetic factors such as the Framingham risk score for
cardiovasculardisease.Implementationofgeneticriskprediction
in healthcare requires a series of studies that encompass all
phasesoftranslationalresearch,
1 2startingwithacomprehensive
evaluation of genetic risk prediction.
With increasing numbers of discovered genetic markers that
canbeusedinfuturegeneticriskpredictionstudies,itiscrucial
to enhance the quality of the reporting of these studies, since
valid interpretation could be compromised by the lack of
reporting of key information. Information that is often missing
includesdetailsinthedescriptionofhowthestudywasdesigned
and conducted (eg, how genetic variants were selected and
coded,howriskmodelsorgeneticriskscoreswereconstructed,
andhowriskcategorieswerechosen),orhowtheresultsshould
be interpreted. An appropriate assessment of the study’s
strengths and weaknesses is not possible without this
information. There is ample evidence that prediction research
often suffers from poor design and bias, and these may also
have an impact on the results of the studies and on models of
disease outcomes based on these studies.
3-5 Although most
prognostic studies published to date claim significant results,
6 7
very few translate to clinically useful applications. Just as for
observational epidemiological studies,
8 poor reporting
complicates the use of the specific study for research, clinical,
orpublichealthpurposesandhampersthesynthesisofevidence
across studies.
Reporting guidelines have been published for various research
designs,
9 and these contain many items that are also relevant to
genetic risk prediction studies. In particular, the guidelines for
genetic association studies (STREGA) have relevant items on
the assessment of genetic variants, and the guidelines for
observational studies (STROBE) have relevant items about the
reporting of study design. The guidelines for diagnostic studies
(STARD) and those for tumour marker prognostic studies
(REMARK) include relevant items about test evaluation; the
REMARK guidelines also have relevant items about risk
prediction.
5-12However,noneoftheseguidelinesarefullysuited
to genetic risk prediction studies, an emerging field of
investigation with specific methodological issues that need to
be addressed, such as the handling of large numbers of genetic
variants (from 10s to 10 000s) and flexibility in handling such
large numbers in analyses. We organised a two day workshop
with an international group of risk prediction researchers,
epidemiologists, geneticists, methodologists, statisticians, and
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RESEARCH METHODS & REPORTINGjournal editors to develop recommendations for the reporting
of genetic risk prediction studies (GRIPS).
Genetic risk prediction studies
Genetic risk prediction studies typically develop or validate
models that predict the risk of disease, but they are also being
investigatedforuseinpredictingprognosticoutcome,treatment
response, or treatment related harms. Risk prediction models
are statistical algorithms, which may be simple genetic risk
scores (for example, risk allele counts), may be based on
regression analyses (for example, weighted risk scores or
predicted risks), or may be based on more complex analytical
approaches such as support vector machine learning or
classification trees. The risk models may be based on genetic
variants only or include both genetic and non-genetic risk
factors.
13
Aims and use of the GRIPS statement
The 25 items of the GRIPS statement are intended to maximise
the transparency, quality, and completeness of reporting on
research methodology and findings in a particular study. It is
important to emphasise that these recommendations are
guidelines only for how to report research and do not prescribe
how to perform genetic risk prediction studies. The guidelines
do not support or oppose the choice of any particular study
designormethod—forexample,theguidelinesrecommendthat
the study population should be described but do not specify
which population is preferred in a particular study.
The intended audience for the reporting guidelines is broad and
includes epidemiologists, geneticists, statisticians, clinician
scientists, and laboratory based investigators who undertake
genetic risk prediction studies, as well as journal editors and
reviewerswhohavetoappraisethedesign,conduct,andanalysis
of such studies. In addition, it includes “users” of such studies
who wish to understand the basic premise, design, and
limitations of genetic prediction studies in order to interpret the
results for their potential application in healthcare. These
guidelines are also intended to ensure that essential data from
future genetic risk prediction studies are presented in
standardised form, which will facilitate information synthesis
as part of systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide array of
risk prediction studies, because GRIPS focuses on the main
aspects of the design and analysis of risk prediction studies.
GRIPS does not address randomised trials that may be
performed to test risk models, nor does it specifically address
decision analyses, cost effectiveness analyses, assessment of
healthcare needs, or assessment of barriers to healthcare
implementation.
14 Once the performance of a risk model has
beenestablished,thesenextstepstowardimplementationrequire
further evaluation.
10 15 For the reporting of these studies, which
go beyond the assessment of genetic risk models as such,
additionalrequirementsapply.However,properdocumentation
of genetic predictive research according to GRIPS might
facilitate the translation of research findings into clinical and
public health practice.
Development of the GRIPS statement
The GRIPS statement was developed by a multidisciplinary
panel of 25 risk prediction researchers, epidemiologists,
geneticists, methodologists, statisticians, and journal editors,
sevenofwhomwerealsopartoftheSTREGAinitiative.
11They
attended a two day meeting in Atlanta, Georgia, USA, in
December 2009 that was sponsored by the US Centers for
DiseaseControlandPreventiononbehalfoftheHumanGenome
Epidemiology Network (HuGENet).
16 Participants discussed a
draftversionoftheguidelinesthatwaspreparedanddistributed
before the meeting. This draft version was developed on the
basis of existing reporting guidelines—namely, STREGA,
11
REMARK,
5 and STARD.
12 These were selected out of all
available guidelines (see www.equator-network.org) because
oftheirfocusonobservationalstudydesignsandgeneticfactors
(STREGA),predictionmodels(REMARK),andtestevaluation
(REMARK and STARD).
During the meeting, methodological issues pertinent to risk
prediction studies were addressed in presentations. Workshop
participants were asked to change, combine, or delete proposed
items and add additional items if necessary. Participants had
extensivepost-meetingelectroniccorrespondence.Toharmonise
our recommendations for genetic risk prediction studies with
previous guidelines, we chose the same wording for the items
wherever possible. Finally, we tried to create consistency with
previous guidelines for the evaluation of risk prediction studies
of cardiovascular diseases and cancer.
2 17 The table⇓ gives the
final version of the checklist.
GRIPS explanation and elaboration article
To accompany this GRIPS statement, we have written an
explanation and elaboration document,
18 modelled on those
developed for other reporting guidelines.
19-22 The document
illustrates each item with at least one published example that
we consider transparent in reporting, explains the rationale for
its inclusion in the checklist, and presents details of the items
that need to be addressed to ensure transparent reporting. The
explanation and elaboration document was produced after the
meeting. The document was prepared by a small subgroup and
shared with all workshop participants for additional revisions
and final approval.
Concluding remarks and future directions
High quality reporting reveals the strengths and weaknesses of
empirical studies, facilitates the interpretation of the scientific
and healthcare relevance of the results—especially within the
frameworkofsystematicreviewsandmeta-analyses—andhelps
build a solid evidence base for moving genomic discoveries
into applications in healthcare practice. The GRIPS guidelines
were developed to improve the transparency, quality, and
completenessofthereportingofgeneticriskpredictionstudies.
As outlined in the introduction, GRIPS does not prescribe how
studies should be designed, conducted, or analysed, and
therefore the guidelines should not be used to assess the quality
of empirical studies.
23 The guidelines should be used only to
check whether all essential items are adequately reported.
Finally, the methodology for designing and assessing genetic
risk prediction models is still developing. For example, newer
measuresofreclassificationwerefirstintroducedin2007,
24and
several alternative reclassification measures have been
proposed.
25Whichmeasurestoapplyandwhentousemeasures
of reclassification are still subject to ongoing evaluation and
discussion.
26Furthermore,alternativestrategiesforconstructing
risk models other than simple regression analyses are being
explored, and these may add increased complexity to the
reporting. In formulating the items of the GRIPS statement,
these methodological advances were anticipated. It is for this
reason that the GRIPS statement recommends how a study
should be reported and not how a study should be conducted or
analysed. Therefore, methodological and analytical
developments will not immediately impact the validity and
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RESEARCH METHODS & REPORTINGrelevanceoftheitems,buttheGRIPSstatementwillbeupdated
when this is warranted by essential new developments in the
construction and evaluation of genetic risk models.
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RESEARCH METHODS & REPORTINGSummary points
• The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application
of genetic risk models for clinical and public health practice
• The number of studies assessing the predictive ability is steadily increasing, but the quality and completeness of
reporting varies
• A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25
items recommended for strengthening the reporting of genetic risk prediction studies (GRIPS), building on the principles
established by prior reporting guidelines
• These recommendations aim to enhance the transparency of study reporting and thereby improve the synthesis and
application of information from multiple studies that might differ in design, conduct, or analysis
Table
Table 1| Reporting recommendations for evaluations of risk prediction models that include genetic variants
Recommendation Item No Report section
Title and abstract
(a) Identify the article as a study of risk prediction using genetic factors 1
(b) Use recommended keywords in the abstract: genetic or genomic, risk, prediction
Introduction
Explain the scientific background and rationale for the prediction study 2 Background and rationale
Specify the study objectives and state the specific model(s) that is/are investigated. State if the study
concerns the development of the model(s), a validation effort, or both
3 Objectives
Methods
Specify the key elements of the study design and describe the setting, locations, and relevant dates, including
periods of recruitment, follow-up, and data collection
4* Study design and setting
Describe eligibility criteria for participants, and sources and methods of selection of participants 5* Participants
Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using
a widely used nomenclature system
6* Variables: definition
(a) Describe sources of data and details of methods of assessment (measurement) for each variable 7* Variables: assessment
(b) Give a detailed description of genotyping and other laboratory methods
(a) Describe how genetic variants were handled in the analyses 8 Variables: coding
(b) Explain how other quantitative variables were handled in the analyses. If applicable, describe which
groupings were chosen, and why
Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables
were initially examined or considered for inclusion in models. Include details of any variable selection
procedures and other model building issues. Specify the horizon of risk prediction (eg, 5 year risk)
9 Analysis: risk model construction
Specify the procedure and data used for the validation of the risk model 10 Analysis: validation
Specify how missing data were handled 11 Analysis: missing data
Specify all measures used for the evaluation of the risk model including, but not limited to, measures of
model fit and predictive ability
12 Analysis: statistical methods
Describe all subgroups, interactions, and exploratory analyses that were examined 13 Analysis: other
Results
Report the numbers of individuals at each stage of the study. Give reasons for non-participation at each
stage. Report the number of participants not genotyped and reasons why they were not genotyped
14* Participants
Report demographic and clinical characteristics of the study population, including risk factors used in the
risk modelling
15* Descriptives: population
Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted
estimates and their precision from the full risk model(s) for each variable
16 Descriptives: model estimates
Report distributions of predicted risks and/or risk scores 17* Risk distributions
Report measures of model fit and predictive ability, and any other performance measures, if pertinent. 18 Assessment
Report any validation of the risk model(s) 19 Validation
Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent 20 Other analyses
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Recommendation Item No Report section
Discussion
Discuss limitations and assumptions of the study, particularly those concerning study design, selection of
participants, and measurements and analyses, and discuss their impact on the results of the study.
21 Limitations
Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence
22 Interpretation
Discuss the generalisability and, if pertinent, the healthcare relevance of the study results 23 Generalisability
Other
State whether databases for the analysed data, risk models, and/or protocols are or will become publicly
available and if so, how they can be accessed
24 Supplementary information
Give the source of funding and the role of the funders for the present study. State whether there are any
conflicts of interest
25 Funding
* Marked items should be reported for every population in the study.
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